What is Crescent Biopharma, Inc.'s (CBIO) StockRank?

MoatMap's StockRank for Crescent Biopharma, Inc. (CBIO) is 26/100, with a Sell signal. This is a composite score combining Quality (29), Value (25), and Momentum (58) factor ranks across MoatMap's 20,000+ stock universe.

Does Crescent Biopharma, Inc. have an economic moat?

Crescent Biopharma, Inc. (CBIO) has a Quality factor score of 29/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Crescent Biopharma, Inc. a buy, hold, or sell?

MoatMap's current signal for Crescent Biopharma, Inc. (CBIO) is Sell, based on a StockRank of 26/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Crescent Biopharma, Inc. in?

Crescent Biopharma, Inc. (CBIO) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

CBIO

Sell

Crescent Biopharma, Inc. · Healthcare · United States · $659M · Avg Vol: $4M/d

StockRank

Get insider-trade alerts

P/E (TTM)

—

ROE

-75.8%

D/E

0.0x

Dividend %

—

COMPANY DESCRIPTION

Crescent Biopharma, Inc. is a biopharmaceutical company focused on developing innovative therapies for unmet medical needs. While specific product details may vary, the company typically leverages scientific advancements to address serious diseases through novel drug discovery and development. Crescent Biopharma aims to carve out a niche in specific therapeutic areas by bringing differentiated treatments to market, contributing to the broader healthcare landscape.

FINANCIAL SUMMARY (USD)

Year	2024	2025	TTM	2026E	Fwd CAGR
Revenue	—	10.8M	11.9M	10.8M	0.0%
EPS	—	-12.81	—	—	—
Shares	19.5M	30.4M	37.1M	—	—
Debt	37.5M	1.6M	1.4M	—	—
Equity	-15.5M	203.0M	—	—	—
Op CF	—	-71.5M	-72.7M	—	—
Inv CF	—	-72.9M	—	—	—
Fin CF	—	323.0M	—	—	—

Loading 1Y...

PRICE (1Y)+17.9%

SMA 50SMA 200

$17.75

RSI (14)

53.1

52W High

$27.41

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

-73.3%10.6

ROE

-75.8%13.1

GP/Assets

4.9%19.7

Op. Margin

-1432.6%6.3

FCF/Assets

—N/A

Piotroski

340.0

Int. Cover

-50.0x6.2

D/E Ratio

0.01x85.2

Current Ratio

9.66x85.8

Value

P/E (TTM)

—N/A

EV/EBITDA

-3.6x25.0

P/FCF

—N/A

P/B

3.8x36.2

P/S

56.3x10.0

Div Yield

—N/A

Momentum

52W High %

65%41.5

RS 6M

34%87.1

SMA 50/200

1.09x76.3

EPS Rev 4W

+11.7%90.5

EPS Rev 12W

+10.7%86.8

EPS Improve

-1779%0.2

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$659M

P/E (Forward)

-6.9x

Gross Margin

100.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CBIO are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
CBIO	Crescent Biopharma, Inc.(you)	$659M	26	Sell
VSTM	Verastem, Inc.	$654M	25	Sell
DRUG	Bright Minds Biosciences Inc.	$714M	25	Sell
MPLT	MapLight Therapeutics, Inc.	$584M	26	Sell
STTK	Shattuck Labs, Inc.	$707M	24	Sell
AURA	Aura Biosciences, Inc.	$767M	26	Sell
NVCT	Nuvectis Pharma, Inc.	$775M	27	Sell
FDMT	4D Molecular Therapeutics, Inc.	$810M	26	Sell
SGMT	Sagimet Biosciences Inc.	$656M	34	Sell
ACHV	Achieve Life Sciences, Inc.	$834M	22	Sell

Peer medians: ROE -25.6% · P/E 29.5x · Gross margin 58.7%

Crescent Biopharma, Inc. (CBIO): Stock Score Summary

Crescent Biopharma, Inc. (CBIO) has a MoatMap StockRank of 26/100 based on Quality (29/100), Value (25/100), and Momentum (58/100) factor scores. The current signal is SELL.

Key Financial Metrics

Price	$17.75
Market Cap	$659M
P/E (Forward)	-6.85
Price/Book	3.78
Return on Equity	-75.8%
Return on Invested Capital	-73.3%
Debt/Equity	0.01x
Gross Margin	100.0%
Operating Margin	-1432.6%

Crescent Biopharma, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Crescent Biopharma, Inc.’s (CBIO) StockRank?: MoatMap’s StockRank for Crescent Biopharma, Inc. (CBIO) is 26/100, with a Sell signal. It is a composite of Quality (29), Value (25), and Momentum (58) factor ranks across MoatMap’s 20,000+ stock universe.
Does Crescent Biopharma, Inc. have an economic moat?: Crescent Biopharma, Inc. (CBIO) has a Quality factor score of 29/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Crescent Biopharma, Inc. a buy, hold, or sell?: MoatMap’s current signal for Crescent Biopharma, Inc. (CBIO) is Sell, based on a StockRank of 26/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Crescent Biopharma, Inc. in?: Crescent Biopharma, Inc. (CBIO) operates in the Healthcare sector, specifically the Biotechnology industry (United States).